Safety and Drug Absorption of Orally Administered Oleylphosphocholine (OlPC) in Healthy Adults
Safety and Pharmacokinetics of Oleylphosphocholine (OlPC), Administered Orally in Healthy Adults: A Phase 1, Single Center, Open-label, Staggered, Dose-escalation Trial
Sponsor: University Hospital Tuebingen
Terminated
The risk-benefit ratio changed
Other terminated trials from University Hospital Tuebingen
Other Leishmaniasis trials with similar outcome
A PHASE1 clinical study on Leishmaniasis, this trial is terminated or withdrawn. The trial is conducted by University Hospital Tuebingen and has accumulated 5 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Feb 2024 — Apr 2024 [monthly]
Recruiting PHASE1
-
Dec 2023 — Feb 2024 [monthly]
Recruiting PHASE1
First recorded
Jun 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University Hospital Tuebingen
For direct contact, visit the study record on ClinicalTrials.gov .